Platinum-resistant recurrent or metastatic nasopharyngeal carcinoma
Pembrolizumab (200 mg IV q21d) vs. Pembrolizumab (200 mg IV q21d) + Bevacizumab (7.5 mg/kg IV q21d)
Efficacy
ORR: 58.3% [36.6–77.9] vs. 12.5% [2.7–32.4] (p=0.0010)
mPFS: 13.8 mos [4.2–29.5] vs. 1.6 mos [1.3–2.7] (HR: 0.25 [0.13–0.50])
mOS: 18.5 mos [9.1–NR] vs. 11.7 mos [7.0–16.1]
Safety
Grade ≥3 AEs: 29% vs. 8%
Common Grade ≥3 AEs: thrombosis or bleeding (17% vs. 0%), colitis (4% vs. 0%), cytopenias (4% vs. 0%), hypertension (4% vs. 0%), proteinuria (4% vs. 0%)
